Gowthami Morey Arepally

Gowthami Morey Arepally

Professor of Medicine

Gowthami M. Arepally, M.D. is a Professor of Medicine in the Division of Hematology at Duke University Medical Center.  Her clinical interests are in immune thrombocytopenias, thrombotic disorders, and complement-mediated diseases.  Dr. Arepally’s long-standing research program investigates the immune pathogenesis of heparin induced thrombocytopenia (HIT).  Current laboratory efforts focus on the role of complement activation in antibody production and thrombosis in HIT, studies of complement inhibitors for immune-complex mediated diseases and diagnostic biomarkers of platelet activation.  

Appointments and Affiliations

  • Professor of Medicine
  • Professor of Pathology
  • Associate Professor of Pathology

Contact Information

  • Office Location: Rm 356A Sands Bldg, Research Drive, Durham, NC 27710
  • Office Phone: +1 919 668 1550
  • Email Address: arepa001@mc.duke.edu
  • Websites:


  • University of Pennsylvania, 1997
  • Emory University, 1993
  • Emory University, 1992
  • M.D. Vanderbilt University, 1989

Research Interests

Our laboratory conducts translational studies of hematologic disease. Using heparin induced thrombocytopenia (HIT) as a model disease, we apply in vitro, ex-vivo and in vivo approaches to uncover disease mechanisms, model disease and apply discoveries to patient care. Beyond HIT, our laboratory is investigating biomarkers of venous thrombosis and HIT, complement's role in other immune-complex disorders and mechanisms of classical pathway regulation.

Courses Taught

  • PATHOL 293: Research Independent Study
  • HLTHSCI 528: Basic Science Selective

In the News

Representative Publications

  • Arepally, GM; Hursting, MJ, Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay results., J Thromb Thrombolysis, vol 26 no. 1 (2008), pp. 55-61 [10.1007/s11239-008-0217-y] [abs].
  • Suvarna, S; Qi, R; Hollingsworth, JW; Arepally, GM, Platelet factor 4-heparin complexes trigger immune responses independently of the MyD88 pathway., Br J Haematol, vol 142 no. 4 (2008), pp. 671-673 [10.1111/j.1365-2141.2008.07240.x] [abs].
  • Suvarna, S; Espinasse, B; Qi, R; Lubica, R; Poncz, M; Cines, DB; Wiesner, MR; Arepally, GM, Determinants of PF4/heparin immunogenicity., Blood, vol 110 no. 13 (2007), pp. 4253-4260 [10.1182/blood-2007-08-105098] [abs].
  • Cines, DB; Rauova, L; Arepally, G; Reilly, MP; McKenzie, SE; Sachais, BS; Poncz, M, Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly., J Clin Apher, vol 22 no. 1 (2007), pp. 31-36 [10.1002/jca.20109] [abs].
  • Suvarna, S; Rauova, L; McCracken, EKE; Goss, CM; Sachais, BS; McKenzie, SE; Reilly, MP; Gunn, MD; Cines, DB; Poncz, M; Arepally, G, PF4/heparin complexes are T cell-dependent antigens., Blood, vol 106 no. 3 (2005), pp. 929-931 [10.1182/blood-2004-12-4955] [abs].